Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches
Abstract Model‐based tumor growth inhibition (TGI) metrics are increasingly used to predict overall survival (OS) data in Phase III immunotherapy clinical trials. However, there is still a lack of understanding regarding the differences between two‐stage or joint modeling methods to leverage Phase I...
Saved in:
Main Authors: | Mathilde Marchand (Author), Antonio Gonçalves (Author), François Mercier (Author), Pascal Chanu (Author), Jin Y. Jin (Author), Jérémie Guedj (Author), René Bruno (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer
by: Antonio Gonçalves, et al.
Published: (2024) -
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework
by: Phyllis Chan, et al.
Published: (2021) -
Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel
by: Sreenath M. Krishnan, et al.
Published: (2021) -
Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
by: Gérald E. Piérard, et al.
Published: (2012) -
Association of survival with adjuvant chemotherapy in patients with stage IB gastric cancer: a multicentre, observational, cohort studyResearch in context
by: Xianchun Gao, et al.
Published: (2024)